Thibault Boutherin
Stock Analyst at Morgan Stanley
(3.65)
# 2,193
Out of 4,683 analysts
161
Total ratings
63.2%
Success rate
7.8%
Average return
Main Sectors:
Stocks Rated by Thibault Boutherin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SWX: NOVN Novartis AG | Maintained: Buy | CHF 135.00 | CHF 127.18 | +6.15% | 13 | Jun 25, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Hold | kr 270.00 → kr 250.00 | kr 309.32 | -19.18% | 6 | May 7, 2026 | |
| SWX: GALD Galderma Group AG | Maintained: Hold | CHF 155.00 → CHF 160.00 | CHF 171.00 | -6.43% | 9 | Apr 27, 2026 | |
| NVS Novartis AG | Maintained: Buy | $143 → $170 | $157.54 | +7.91% | 3 | Mar 26, 2026 | |
| ETR: BAYN Bayer Aktiengesellschaft | Maintained: Buy | €40.00 → €53.00 | €49.11 | +7.92% | 5 | Mar 11, 2026 | |
| BME: GRF Grifols, S.A. | Downgraded: Hold | €12.00 → €11.00 | €10.04 | +9.62% | 7 | Mar 10, 2026 | |
| NVO Novo Nordisk | Upgraded: Hold | $42 → $40 | $47.19 | -15.24% | 5 | Mar 3, 2026 | |
| INDV Indivior Pharmaceuticals | Maintained: Buy | $28 → $36 | $35.83 | +0.49% | 11 | Dec 3, 2025 | |
| ETR: MRK Merck KGaA | Maintained: Hold | €130.00 → €135.00 | €138.65 | -2.63% | 5 | Dec 3, 2025 | |
| SWX: LONN Lonza Group AG | Maintained: Buy | CHF 650.00 | CHF 587.80 | +10.58% | 10 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 → $10 | $4.91 | +103.67% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | CHF 38.00 → CHF 50.00 | CHF 70.66 | -29.24% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €300.00 | €244.40 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €250.00 | €192.00 | n/a | 3 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €715.00 | €896.20 | n/a | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | 2,100p → 2,400p | 1,640p | n/a | 15 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $14 | $1.95 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | €12.00 | €3.35 | n/a | 1 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 912p | 1,297p | n/a | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €120.00 | €165.90 | n/a | 18 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $37 → $40 | $87.64 | n/a | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | CHF 4.00 → CHF 1.00 | CHF 5.68 | n/a | 11 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | €0.88 → €105.00 | €220.65 | n/a | 12 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $16 | $7.90 | n/a | 4 | Dec 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €11.50 → €11.00 | €10.50 | n/a | 5 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $10 | $37.92 | n/a | 2 | Oct 4, 2023 |
Novartis AG
Jun 25, 2026
Maintained: Buy
Price Target: CHF 135.00
Current: CHF 127.18
Upside: +6.15%
Novo Nordisk A/S
May 7, 2026
Maintained: Hold
Price Target: kr 270.00 → kr 250.00
Current: kr 309.32
Upside: -19.18%
Galderma Group AG
Apr 27, 2026
Maintained: Hold
Price Target: CHF 155.00 → CHF 160.00
Current: CHF 171.00
Upside: -6.43%
Novartis AG
Mar 26, 2026
Maintained: Buy
Price Target: $143 → $170
Current: $157.54
Upside: +7.91%
Bayer Aktiengesellschaft
Mar 11, 2026
Maintained: Buy
Price Target: €40.00 → €53.00
Current: €49.11
Upside: +7.92%
Grifols, S.A.
Mar 10, 2026
Downgraded: Hold
Price Target: €12.00 → €11.00
Current: €10.04
Upside: +9.62%
Novo Nordisk
Mar 3, 2026
Upgraded: Hold
Price Target: $42 → $40
Current: $47.19
Upside: -15.24%
Indivior Pharmaceuticals
Dec 3, 2025
Maintained: Buy
Price Target: $28 → $36
Current: $35.83
Upside: +0.49%
Merck KGaA
Dec 3, 2025
Maintained: Hold
Price Target: €130.00 → €135.00
Current: €138.65
Upside: -2.63%
Lonza Group AG
Dec 3, 2025
Maintained: Buy
Price Target: CHF 650.00
Current: CHF 587.80
Upside: +10.58%
Dec 3, 2025
Maintained: Buy
Price Target: $14 → $10
Current: $4.91
Upside: +103.67%
Dec 3, 2025
Maintained: Hold
Price Target: CHF 38.00 → CHF 50.00
Current: CHF 70.66
Upside: -29.24%
Apr 22, 2025
Maintained: Buy
Price Target: €300.00
Current: €244.40
Upside: n/a
Apr 22, 2025
Maintained: Buy
Price Target: €250.00
Current: €192.00
Upside: n/a
Mar 5, 2025
Maintained: Buy
Price Target: €715.00
Current: €896.20
Upside: n/a
Feb 12, 2025
Maintained: Hold
Price Target: 2,100p → 2,400p
Current: 1,640p
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: $14
Current: $1.95
Upside: n/a
Jul 29, 2024
Downgraded: Hold
Price Target: €12.00
Current: €3.35
Upside: n/a
Jul 15, 2024
Maintained: Buy
Price Target: 912p
Current: 1,297p
Upside: n/a
May 15, 2024
Maintained: Hold
Price Target: €120.00
Current: €165.90
Upside: n/a
May 8, 2024
Maintained: Hold
Price Target: $37 → $40
Current: $87.64
Upside: n/a
Apr 3, 2024
Maintained: Sell
Price Target: CHF 4.00 → CHF 1.00
Current: CHF 5.68
Upside: n/a
Mar 25, 2024
Upgraded: Hold
Price Target: €0.88 → €105.00
Current: €220.65
Upside: n/a
Dec 29, 2023
Maintained: Hold
Price Target: $16
Current: $7.90
Upside: n/a
Nov 13, 2023
Maintained: Hold
Price Target: €11.50 → €11.00
Current: €10.50
Upside: n/a
Oct 4, 2023
Maintained: Hold
Price Target: $10
Current: $37.92
Upside: n/a